Long-term safety from the raltegravir clinical development program. - Wikidata - awgldk - TriplyDB

Long-term safety from the raltegravir clinical development program.

Long-term safety from the raltegravir clinical development program.

http://www.wikidata.org/entity/Q35701258

about

Neurological and psychiatric adverse effects of antiretroviral drugs.96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.Neuropsychiatric Effects of HIV Antiviral Medications.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.Psychiatric Symptoms in Patients Receiving Dolutegravir.Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND.Cost-effectiveness of raltegravir in HIV/AIDS.Antiretroviral therapy: effects on orofacial health and health care.Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.A safety evaluation of raltegravir for the treatment of HIV.

P2860

Q34039419-223C8849-07F8-49B2-A45F-9AF8998DA134 Q34341541-7686E1DE-AD21-4EAF-970D-A780495C11F2 Q34537705-B04D3066-554B-45D9-9D25-6E16E7DADEFB Q35789343-4EC15E61-416F-42EA-ABA7-901EF305ED31 Q36018556-E74A9746-D386-4D7A-BEBC-5924815A0254 Q36759898-2E34CB97-C1AA-4FD0-9503-796258B54918 Q37659135-553E149D-5E92-47E8-A7E8-271FDFA050A3 Q37721505-1740AD10-2079-44F1-8D3B-C2CB1155942B Q37958046-D710A9EE-C95E-48BC-BF35-B8133032F917 Q38093238-D271F84D-7C66-4C95-B9D5-E333131405B2 Q38860427-E0B31C00-B596-42EB-AEF6-869451B9B61E Q38882614-166609CA-5B8F-4AEB-AB75-33564A69096E Q40051820-8A22AC82-E461-4BA0-A69A-8C97F1932526 Q41990454-B0FE687E-DDB4-4487-8E47-8242BE246A0F Q47377203-7C64C7EE-1639-4CA2-814F-6E20D945A34F

P2860

Long-term safety from the raltegravir clinical development program.

http://www.wikidata.org/entity/Q35701258

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Long-term safety from the raltegravir clinical development program.

@ast

Long-term safety from the raltegravir clinical development program.

@en

type

label

Long-term safety from the raltegravir clinical development program.

@ast

Long-term safety from the raltegravir clinical development program.

@en

prefLabel

Long-term safety from the raltegravir clinical development program.

@ast

Long-term safety from the raltegravir clinical development program.

@en

P1433

Q35701258-BEB59836-A29A-4372-9F2C-F739F6BCF2B0

P1476

Q35701258-AC0672F8-7075-41C4-AFA0-34450976D9F4

P2093

Q35701258-0DC2A5A7-735D-4484-8DC2-0B4758D5D0D0

Q35701258-1DE4A62C-3D57-4CF6-9EC7-F806C16A4A19

Q35701258-28125F0A-E3F0-49A1-887B-94EA39ABFAD8

Q35701258-2A1F0099-C19A-46EC-B2F7-5CA3D7C13F80

Q35701258-49D24547-4B3A-4C24-A4ED-E19B9131FE60

Q35701258-507DF1FA-C020-4FF3-8498-DE1994A0EC03

Q35701258-56AD287A-6AFB-4E4E-B481-7BCBD8AB6199

Q35701258-60C308B6-CC45-48C1-80D1-7780CE4BEA75

Q35701258-82F0562D-5B8A-4E43-AB8C-DA325DE58855

Q35701258-F01ABC8B-BB77-46CD-966F-B11FD7C2E667

P2860

Q35701258-0643D8BC-077A-45AB-A4F7-55348B4DE8D5

Q35701258-070F363F-6F33-40C7-921A-ABDF29A39F49

Q35701258-093EC1E1-2578-489F-8219-69FF71E363C8

Q35701258-0A31D425-DE80-4770-8E1B-FB8C668ED3CC

Q35701258-123DA513-D1AF-4D9C-BC4D-C59D63B75E25

Q35701258-1CFAFF7E-1B57-4ADF-808A-FC18EA6E8EF4

Q35701258-2047B68D-515C-4475-84A8-D15450A6B786

Q35701258-49AEB354-DDD0-4D84-8412-B74D8DADA66F

Q35701258-4BFD9EF1-1A46-47BC-A6F0-BE810ED8B91E

Q35701258-50E971F7-9150-4056-BBF0-9BF17CB2DD2C

P304

Q35701258-45F074BE-12F1-4143-874E-D92BBC2E8EB7

P31

Q35701258-BCF271EB-A419-415C-9F67-78E6BB504F85

Q35701258-d9397730-d765-463e-b32d-49da05f8acf3

P356

Q35701258-52F9065C-8B33-491F-83B7-345AE54142DD

P433

Q35701258-20DB6237-9BB5-4D58-B782-D27128FBCA18

P478

Q35701258-0F8B8CB2-D354-40F8-BC8C-D8F1654584B7

P577

Q35701258-F0836376-E90D-44FA-9A76-6FE207D0C545

P5875

Q35701258-CEDA1780-23AE-402B-97AC-25B5F7B93ECB

P698

Q35701258-F9BB367D-9C1E-460F-B902-DE33D6B62D69

P932

Q35701258-9A5C989E-E2FC-4AD6-B3F3-F5EA7B923CEC

P356

157016211794582650

P1433

Current HIV Research

P1476

Long-term safety from the raltegravir clinical development program.

@en

P2093

Bach-Yen T Nguyen

http://www.w3.org/2001/XMLSchema#string

Deborah D Brown

http://www.w3.org/2001/XMLSchema#string

Fabio Lievano

http://www.w3.org/2001/XMLSchema#string

Hedy Teppler

http://www.w3.org/2001/XMLSchema#string

Heidi P Lehman

http://www.w3.org/2001/XMLSchema#string

Hong Wan

http://www.w3.org/2001/XMLSchema#string

Peter Sklar

http://www.w3.org/2001/XMLSchema#string

Randi Y Leavitt

http://www.w3.org/2001/XMLSchema#string

T Christopher Mast

http://www.w3.org/2001/XMLSchema#string

Xia Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Raltegravir with optimized background therapy for resistant HIV-1 infection

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

Depression in patients with HIV infection.

Abacavir: a review of its clinical potential in patients with HIV infection.

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.

Immune restoration disease in HIV patients: aberrant immune responses after antiretroviral therapy.

HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.

Immune restoration disease after antiretroviral therapy.

Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.

P304

40-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/157016211794582650

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49721397

http://www.w3.org/2001/XMLSchema#string

P698

21198432

http://www.w3.org/2001/XMLSchema#string

P932

3267161

http://www.w3.org/2001/XMLSchema#string